teleo-codex/domains/health/psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability.md

type	domain	description	confidence	source	created	title	agent	sourced_from	scope	sourcer	challenges	related	supports	reweave_edges
claim	health	COMP005 trial demonstrates MADRS -3.6 point improvement (p<0.001) with benefits maintained through 26 weeks from a single 25mg dose, marking the first psychedelic to reach Phase 3 efficacy threshold	experimental	Compass Pathways COMP005 Phase 3 trial (n=258, 32 US sites)	2026-05-10	Psilocybin achieves positive Phase 3 evidence for treatment-resistant depression with single-dose 26-week durability representing the first FDA-approvable psychedelic	vida	health/2025-06-23-compass-pathways-comp005-psilocybin-phase3-trd.md	causal	Compass Pathways	prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software	the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability psychedelic-therapy-regulatory-success-requires-active-comparator-or-objective-endpoints-for-highly-psychoactive-compounds	Trump's April 2026 Executive Order on psychedelics represents the first federal bipartisan commitment to Schedule I psychedelic drug development pathways, signaling regulatory environment shift that de-risks clinical investment through existing frameworks rather than new legislation	Trump's April 2026 Executive Order on psychedelics represents the first federal bipartisan commitment to Schedule I psychedelic drug development pathways, signaling regulatory environment shift that de-risks clinical investment through existing frameworks rather than new legislation|supports|2026-05-11

Psilocybin achieves positive Phase 3 evidence for treatment-resistant depression with single-dose 26-week durability representing the first FDA-approvable psychedelic

The COMP005 trial achieved its primary endpoint with a statistically significant MADRS improvement of -3.6 points versus placebo (95% CI [-5.7, -1.5], p<0.001) at week 6 in 258 participants with treatment-resistant depression. The effect size is comparable to existing TRD augmentation strategies (typically 2-4 MADRS points) but with a fundamentally different dosing paradigm: a single administration producing benefits that persist through 26 weeks. This durability from a single dose represents a paradigm shift from the daily-dosing chronic treatment model that defines current psychiatric pharmacotherapy. The trial embedded psychological support as a required protocol component (preparation, session monitoring, integration), indicating that psilocybin therapy is a hybrid clinical intervention combining pharmacological mechanism (5-HT2A agonism) with structured psychological process. Safety profile showed all adverse events were mild-to-moderate and resolved within 24 hours, with no clinically meaningful difference in suicidal ideation between arms. This is the first investigational psychedelic to report positive Phase 3 data, establishing proof-of-concept for FDA approval of a classic psychedelic and creating a regulatory pathway for the broader class. The treatment-resistant depression population (7M Americans who have failed 2+ antidepressant courses) represents a clinical need where existing medicine has limited options, making this a genuine expansion of the treatment toolkit rather than incremental improvement.

Extending Evidence

Source: Journal of Psychoactive Drugs PMC12304229, Oregon facilitator workforce survey 2023-2025

Oregon's real-world implementation shows facilitators specializing in trauma (83%), mental health disorders (69%), and consciousness exploration (68%), with mean planned session cost of $1,388 — below current market of $1,500-3,000 but still unaffordable for most potential TRD patients without insurance coverage. The 7.5% capacity utilization (4,500 actual vs 60,000 theoretical clients/year) demonstrates that clinical efficacy alone is insufficient for population-level access.